Details : AI-based Stain-free imaging technology will be utilized to analyze and quantify collagen-associated parameters as part of Galecto's Phase 2a trial for its oral LOXL2 inhibitor GB2064 in myelofibrosis.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Undisclosed
October 20, 2021
Lead Product(s) : PAT-1251
Therapeutic Area : Trauma (Emergency, Injury, Surgery)
Study Phase : Phase II
Sponsor : Pharmakea therapeutics
Deal Size : Undisclosed
Deal Type : Partnership
Galecto to merge with onetime Celgene partner PharmAkea
Details : The two firms will combine & put in robust fibrosis and cancer services, including a recently inhaled galectin-3 modulator ph IIb for the potential treatment of idiopathic pulmonary fibrosis.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Undisclosed
January 07, 2020
Lead Product(s) : PAT-1251
Therapeutic Area : Trauma (Emergency, Injury, Surgery)
Highest Development Status : Phase II
Sponsor : Pharmakea therapeutics
Deal Size : Undisclosed
Deal Type : Partnership
Lead Product(s) : PAT-1251
Therapeutic Area : Undisclosed
Study Phase : Phase I
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : PAT-1251 is a Other Small Molecule drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of undefined medical condition.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
August 02, 2016
Lead Product(s) : PAT-1251
Therapeutic Area : Undisclosed
Highest Development Status : Phase I
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Reset All
